Impact Biomedical corrects merger exchange ratio, sets reverse stock split

Impact Biomedical corrected the exchange ratio for its proposed merger with Zoar Limited: Impact holders will receive one Zoar share for each Impact share held after the reverse split, rather than the previously stated one Zoar share per four Impact shares. Impact will implement a 1-for-12.62 reverse stock split effective September 23, 2026, reducing shares outstanding to about 8.54 million from 107.82 million. The correction and reverse split are administrative transaction steps, while Zoar's Form F-4 registration statement remains under SEC review.

Analysis

The correction changes the economic interpretation of the transaction materially: holders appear to receive one Zoar share for each post-split IBO share, rather than the previously communicated one-for-four outcome. That removes a likely technical overhang from perceived exchange dilution, but it does not create operating value; the relevant valuation question is Zoar's implied fully diluted equity value versus IBO's post-split capitalization and the terms disclosed in the F-4.

Near term, the 1-for-12.62 split may lift the nominal share price but leaves enterprise value unchanged and can reduce liquidity once the float is compressed. The absence of a corresponding reduction in authorized shares preserves future dilution capacity, an important downside consideration for a micro-cap issuer pursuing a merger. Rounding fractional positions upward is immaterial economically except for tiny odd-lot holders.

The actionable catalyst is SEC review and eventual effectiveness of the F-4, not the split date itself. Until the registration statement provides audited financials, pro forma ownership, cash runway, contingent liabilities and any financing commitments, the transaction cannot be underwritten on fundamentals. A persistent premium in IBO to the value implied by the final exchange terms would be a technical short/watch opportunity, but borrow availability and wide spreads may make it untradeable.

Key Decisions for Investors

• No directional position in IBO ahead of the September 23 split; treat any nominal-price rally as non-fundamental unless accompanied by disclosed pro forma financials or committed financing.
• Monitor the F-4 for post-merger ownership, cash balance, going-concern language, related-party arrangements and maximum authorized-share capacity. Reassess only after these data permit an implied Zoar valuation comparison.
• Set an event-driven alert for IBO trading materially above its pre-split value adjusted by 12.62x without a change in merger economics; evaluate a small short only if borrow is available and average daily dollar volume supports exit liquidity.
• Thesis is invalidated if the definitive filing shows a well-capitalized Zoar business with independently audited revenue/earnings sufficient to justify a higher pro forma valuation, or if exchange mechanics differ from the corrected post-split interpretation.